Prostate Cell News

Prostate Cell News is an online resource summarizing the latest prostate cell research.

Disruption of Androgen Receptor-Cofactor Interactions by the RNA-Binding Protein FUS/TLS Alters Androgen Signaling in Prostate Cancer

February 6, 2026

[Oncogene] Transcriptomic analysis of the LNCaP prostate cancer cell line shows a significant overlap in genes regulated by FUS and the androgen receptor

Mir-340 Improves the Efficiency of P53 Gene Therapy in Metastatic Prostate Cancer Cells through Downregulation of MDM2

February 6, 2026

[Scientific Reports] Researchers evaluated the impact of miR-340-mediated downregulation of MDM2 on the therapeutic efficacy of p53 gene therapy in p53 non-expressing PC3 cells.

Targeting NXPH4/ALDH1L2 Signaling Suppresses Enzalutamide Resistance in Prostate Cancer

February 6, 2026

[Cell Death Discovery] Investigators conducted gain- and loss-of-function studies in prostate cancer cell lines and mouse subcutaneous xenograft models to elucidate the role of Neurexophilin 4 (NXPH4) in CRPC.

Personalized Intensification of Treatment for Hormone-Sensitive Prostate Cancer

February 6, 2026

[Nature Reviews Clinical Oncology] Scientists discuss the personalized management of both non-metastatic and metastatic hormone-sensitive prostate cancer, including how to select patients for docetaxel, choice of androgen receptor pathway inhibitors and use of radiotherapy to primary and metastatic disease sites.

Integrated Regulation of Ferroptosis in Prostate Cancer Covering Mechanisms, Resistance, and Translational Opportunities

February 6, 2026

[Journal of Molecular Medicine] The authors summarize the multifaceted regulation of ferroptosis in prostate cancer from molecular, metabolic, and microenvironmental perspectives.

Recurrent Immunogenic Neoantigens and Their Cognate T-Cell Receptors in Treatment-Resistant Metastatic Prostate Cancer

February 6, 2026

[Cancer Discovery] Scientists established a novel analysis pipeline, Spot Neoantigens in Metastases, that systematically identifies treatment resistance mutations and their predicted derived neoantigens.

Pfizer Announces 2025 Grant Recipients Driving Innovative Solutions in Cancer Care

February 6, 2026

[Pfizer] Pfizer announced the recipients of a series of grants to help advance oncology research. An investment of $900,000 has been made across different projects to support the development of patient-centric solutions for some of Canada’s most diagnosed cancers: lung, colorectal, prostate, and bladder cancer.

K36 Therapeutics Completes Dosing of First Cohort in Phase I Clinical Trial of KTX-2001 in Prostate Cancer, Announces New CMO

February 6, 2026

[K36 Therapeutics (BioSpace)] K36 Therapeutics, Inc. announced completion of dosing in the first patient cohort of its Phase I clinical trial evaluating KTX-2001, a first-in-class, orally administered, selective NSD2 inhibitor, in patients with metastatic CRPC.

PRDM16 Regulates Prostate Cancer Cell Dormancy and Prevents Bone Metastatic Outgrowth

February 5, 2026

[Cancer Research] Using murine and human prostate cancer cell lines, scientists generated a stress-induced model of dormancy in vitro and demonstrated that the phenotype could be sustained upon intrailiac artery delivery into the bone marrow microenvironment.

Lack of Synergy Between AR-Targeted Therapies and PARP Inhibitors in Homologous Recombination-Proficient Prostate Cancer

February 5, 2026

[Proceedings of the National Academy of Sciences of the United States of America] Investigators profiled the effects of poly (adenosine diphosphate-ribose) polymerase inhibition in prostate cancer models in the presence or absence of androgen receptor inhibition.

Loss of IL1RA Promotes Prostate Cancer Growth and Metastasis by Activating Akt Signaling Pathway

February 5, 2026

[PloS One] Researchers revealed that interleukin-1 receptor antagonist (IL1RA) low expression was associated with prostate cancer progression.

Preclinical Activity of the DLL3-Targeted T-Cell Engager MK-6070 in Neuroendocrine Prostate Cancer

February 5, 2026

[Molecular Cancer Therapeutics] Scientists reported the preclinical activity of MK-6070 in prostate cancer models, showing high specificity and antitumor activity in DLL3-expressing neuroendocrine prostate cancer models both in vitro and in vivo, with T cell activation and tumor infiltration of T cells after treatment.

Published since 2010, Prostate Cell News compiles top scientific journal articles covering the characterization, behavior, and culturing of prostate cells. Additionally, our editorial team curates the latest press releases, technical advances, jobs, and events relevant to the prostate cell research community. Prostate Cell News saves scientists valuable time while keeping them informed in their field, facilitating the rapid exchange of cutting edge research updates and science news.